-+ 0.00%
-+ 0.00%
-+ 0.00%

Barclays Maintains Overweight on Celldex Therapeutics, Raises Price Target to $53

Benzinga·08/07/2026 10:50:10
Listen to the news
Barclays analyst Etzer Darout maintains Celldex Therapeutics (NASDAQ:CLDX) with a Overweight and raises the price target from $48 to $53.